But new research suggests these drugs could be doing more than helping people shed pounds. Scientists at the University of ...

Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

Once boasting up to five million subscribers and backed by the likes of Oprah Winfrey, the company is now trying to shed debt ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS.Research by ...